Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does EMPAGLIFLOZIN Cause Therapy interrupted? 42 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Therapy interrupted have been filed in association with EMPAGLIFLOZIN (Jardiance). This represents 0.1% of all adverse event reports for EMPAGLIFLOZIN.

42
Reports of Therapy interrupted with EMPAGLIFLOZIN
0.1%
of all EMPAGLIFLOZIN reports
4
Deaths
26
Hospitalizations

How Dangerous Is Therapy interrupted From EMPAGLIFLOZIN?

Of the 42 reports, 4 (9.5%) resulted in death, 26 (61.9%) required hospitalization, and 4 (9.5%) were considered life-threatening.

Is Therapy interrupted Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for EMPAGLIFLOZIN. However, 42 reports have been filed with the FAERS database.

What Other Side Effects Does EMPAGLIFLOZIN Cause?

Diabetic ketoacidosis (3,644) Fungal infection (1,941) Blood glucose increased (1,797) Euglycaemic diabetic ketoacidosis (1,769) Weight decreased (1,661) Urinary tract infection (1,439) Ketoacidosis (1,411) Dizziness (1,372) Nausea (1,333) Vomiting (1,201)

What Other Drugs Cause Therapy interrupted?

ADALIMUMAB (5,755) ETANERCEPT (3,397) RELUGOLIX (3,251) CERTOLIZUMAB PEGOL (3,209) LENALIDOMIDE (2,724) UPADACITINIB (1,741) ABATACEPT (1,726) CLOZAPINE (1,722) AMIKACIN (1,283) TOFACITINIB (1,182)

Which EMPAGLIFLOZIN Alternatives Have Lower Therapy interrupted Risk?

EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\LINAGLIPTIN\METFORMIN EMPAGLIFLOZIN vs EMPAGLIFLOZIN\METFORMIN EMPAGLIFLOZIN vs EMSAM EMPAGLIFLOZIN vs EMTRICITABINE

Related Pages

EMPAGLIFLOZIN Full Profile All Therapy interrupted Reports All Drugs Causing Therapy interrupted EMPAGLIFLOZIN Demographics